Das Bergbauunternehmen ist seit Dezember 2019 nicht mehr an einer Börse gelistet. Das Delisting von Voyageur Minerals Ltd. fand aufgrund einer Umstrukturierung statt.
Ältere Artikel von und über die Gesellschaft befinden (sofern vorhanden) sich im Archiv.
Voyageur Pharmaceuticals Ltd. has been working with SGS Canada to advance the Frances Creek high purity barium sulfate project. SGS Canada is currently working with the Frances Creek barite mineralized breccia and has successfully gravity separated a concentrated grade of 98.6% barium sulfate. The samples have been sent to the pharmacy group at SGS [...]
Voyageur Minerals Ltd. is pleased to announce the following matters: Change of Name The Company is pleased to announce that shareholders of the Company approved a change of the Company's name to Voyageur Pharmaceuticals Ltd. Commenting on the name change, CEO Brent Willis stated that "this name change reflects our focus on providing "earth to [...]
Voyageur Minerals Ltd. is pleased to report that it recently closed the second tranche of its previously announced private placement, receiving aggregate gross proceeds of $100,637.48 from the issuance and sale of 1,341,833 units at a price of $0.075 per Unit. Each Unit consists of one common share and one common share purchase warrant entitling [...]
Voyageur Minerals is pleased to announce that it has retained the services of Frontier Merchant Capital Group to provide marketing and financial communications services. FronTier is an investor relations and marketing group with a home office in Toronto. FronTier will assist the company by increasing market awareness for the company using a number [...]
Voyageur Minerals is pleased to announce the formulation and registration submission to Health Canada for its new drug product, MultiXBa. ImagingX Pharmaceuticals has submitted a total of three products for registration to Health Canada, with two more products anticipated to follow in the near term. MultiXBa is a specially formulated low density [...]
